Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative: A Critical Review of Potential Benefits and Drawbacks

By Farnier M.  

American Journal of Cardiovascular Drugs, Vol. 3, Iss. 3, 2003-01 ,pp. : 169-178

Adis International

Access to resources Recommend Favorite

Risk-benefit of HMG-CoA reductase inhibitors in the treatment of HIV protease inhibitor-related hyperlipidaemia

By Penzak Scott R   Chuck Susan K  

Expert Opinion on Drug Safety, Vol. 1, Iss. 1, 2002-05 ,pp. : 5-17

Informa Healthcare

Access to resources Recommend Favorite

EFFECT OF THE NEW HMG-CoA REDUCTASE INHIBITOR CERIVASTATIN (BAY W 6228) ON MIGRATION, PROLIFERATION AND CHOLESTEROL SYNTHESIS IN ARTERIAL MYOCYTES

By Corsini A.   Arnaboldi L.   Raiteri M.   Quarato P.   Faggiotto A.   Paoletti R.   Fumagalli R.  

Pharmacological Research, Vol. 33, Iss. 1, 1996-01 ,pp. : 55-61

Academic Press

Access to resources Recommend Favorite

Pluripotential Mechanisms of Cardioprotection with HMG-CoA Reductase Inhibitor Therapy

By Rosenson R.S.  

American Journal of Cardiovascular Drugs, Vol. 1, Iss. 6, 2001-06 ,pp. : 411-420

Adis International

Access to resources Recommend Favorite

NK-104: a novel synthetic HMG-CoA reductase inhibitor

By Kajinami K.   Mabuchi H.   Saito Y.  

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 11, 2000-11 ,pp. : 2653-2661

Informa Healthcare

Access to resources Recommend Favorite